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was not randomized. As well, although Zamboni found 
no serious complications in 65 MS patients undergoing 
angioplasty of the jugular veins, no large-scale study of 
complications has been reported. These are important 
and valid criticisms.
The public profile of CCSVI in Canada was raised in 
the fall of 2009 by a relatively uncritical article in The 
Globe and Mail (Toronto), and an even more uncritic-
al broadcast on the CTV public affairs program W5.
3,4 
Both portrayed Dr. Zamboni as a pioneer whose theories 
were discounted by conventional medicine and focused 
relatively  little  on  the  criticisms  of  his  studies.  Many 
Canadians  with  MS,  eager  for  an  effective  treatment 
for this miserable disease, have been convinced by Dr. 
Zamboni’s research, and by the testimonials of patients 
who have travelled to other countries to receive the pro-
cedure. They accuse many in the MS scientific commun-
ity  of  being  narrow  minded,  obsessed  with  irrelevant 
scientific niceties, and/or of being in the clutches of the 
pharmaceutical industry.
5 They demand that endovascu-
lar treatment be made available in Canada or, at the very 
least, that a randomized trial of the procedure be started 
immediately.
Into this perfect storm have marched the Canadian 
Institutes of Health Research (CIHR) and the Multiple 
Sclerosis Society of Canada. In September of this year 
they released a summary of the deliberations of a “Joint 
Invitational Meeting” of 15 clinical and scientific experts, 
5 employees of the CIHR, 3 employees of the MS Society, 
and one unidentified person with MS. The panel exam-
ined the scientific literature relating CCSVI and MS, and 
decided that the evidence linking CCSVI and MS was so 
unconvincing that it would be inappropriate at this time 
to perform a clinical trial examining the benefits and 
risks of endovascular treatment as a therapy for MS.
6
Too often, health care interventions are introduced 
on the basis of poor scientific evidence. Therefore, what 
the CIHR and MS Society have attempted to do seems 
admirable to those of us who are proponents of evidence-
based health care and evidence-informed policy-making. 
A review and summary of all research that is relevant to 
important health policy decisions by unbiased experts 
can be used by politicians and policy-makers to make 
policy decisions, in this case whether to fund endovascu-
lar treatment for CCSVI, either as part of a randomized 
trial or through the publicly funded health care system. 
However, we suggest that there are important lessons to 
be learned from this panel’s experience that should be 
considered when constituting future panels that address 
other issues that are at the intersection of science, advo-
cacy and policy-making. 
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I
t  would  be  difficult  to  be  a  canadian  and  be 
unaware  of  the  controversy  regarding  endovascu-
lar treatment for multiple sclerosis (MS). Dr. Paolo 
Zamboni, an Italian physician, has hypothesized that 
MS is caused by a newly discovered abnormality of ven-
ous drainage from the brain that he has called chronic 
cerebrospinal  venous  insufficiency  (CCSVI),  and  that 
endovascular  treatment  of  CCSVI  can  markedly  im-
prove the symptoms of MS.
1,2 The endovascular treat-
ment has been given the rather sensational name “liber-
ation procedure,” invoking the notion of  “setting free.” 
The overwhelming majority of MS researchers dismiss 
Dr. Zamboni’s findings because they fly in the face of 
what is known about the etiology of MS, and because of 
questions about the scientific quality of Dr. Zamboni’s 
work. His studies of the association between CCSVI and 
MS have not been consistently replicated, and his trial 
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view, deliberate about them, and contribute to informed 
recommendations.  
If half a dozen or so such individuals had participated 
in the deliberations, they might have asked questions 
about why proponents of the liberation procedure were 
not members of the panel, and they would have contrib-
uted greatly to the discussion about the appropriateness 
of a clinical trial in the face of poor scientific evidence 
supporting the CCSVI hypothesis and uncertainty about 
the risks of endovascular therapy (which appear to vary 
depending upon whether or not a stent is inserted). They 
would  likely  have  encouraged  the  panel  to  more  fully 
articulate the reasons why a clinical trial should not (or 
possibly should) be conducted now, and might have had 
different views about how to balance information about 
the risks and potential benefits of angioplasty. A number 
of Canadians are now using their own resources to travel 
to other countries to undergo endovascular treatment, 
performed by surgical teams whose quality standards 
are not always clear. Would these patients be better off, 
and policy-makers and the public better informed, if a 
randomized trial were conducted now?  If patients are 
fully informed about current doubts regarding the asso-
ciation of CCSVI and MS, as well as the limitations of 
Zamboni’s non-randomized trial of endovascular treat-
ment,  and  the  potential  side-effects  of  endovascular 
treatment, should they be given the opportunity of par-
ticipating in a trial now? Of course, surgeons and inter-
ventional radiologists should not participate in the trial 
if they feel that the current evidence suggests they are 
likely to do more harm than good to their patients. How-
ever, we know of reputable Canadian vascular surgeons 
who would operate on MS patients in the context of a 
randomized trial. 
Even had greater public membership on the panel not 
changed the recommendations made in the report at all, 
or had the committee not been able to come to a consen-
sus, the very fact that members of the public were on the 
committee  would  likely  have  increased  the  legitimacy 
of the report in the eyes of the public (although not in 
everyone’s).
The public pays for research funded by the CIHR and 
the MS Society of Canada, are affected by the findings, 
and are more likely to be supportive of research in gener-
al if they feel that researchers are more in touch with the 
community. The CIHR has itself, in reference to its Stem 
Cell Oversight Committee, stated “Technical experts will 
provide the Committee access to the latest scientific and 
ethical information, and representatives from the gen-
eral public will represent the views and values of Can-
adians potentially affected by the new technologies.”
11 
Concerns have been raised about the membership of 
the expert panel.
7 No proponents of the liberation pro-
cedure participated in the Invitational Meeting, which 
seems  odd.  Most  scientific  experts  have  some  degree 
of conflict of interest, and these are usually dealt with 
by publicly declaring them, not by excluding a particu-
lar point of view from a panel. Conversely, the potential 
conflicts of interest of the individuals who were on the 
panel were not described in the report, thus allowing 
some to accuse the CIHR of attempting to hide their po-
tential biases.
8 
The panel recommended that no clinical trials of en-
dovascular  treatment  for  CSSVI  should  be  conducted 
until the association between MS and CCSVI has been 
firmly established. The rationale for this recommenda-
tion is sensible: one should not expose MS patients to 
the risks of endovascular therapy—which, although rare, 
can be fatal
9,10—if there is no rational scientific reason to 
think that CCSVI causes MS. However, the panel spent 
little time either justifying their controversial recom-
mendation or discussing potentially opposing points of 
view. We believe that both the panel’s approach to the 
problem and its membership were too narrow to com-
pletely fulfill its mandate. 
It appears to us that the panel addressed three ques-
tions. The first question was whether current evidence 
establishes  that  patients  with  MS  have  a  higher  fre-
quency of CCSVI than patients without MS. The second 
was whether current evidence establishes that the bene-
fits of endovascular treatment in patients with MS out-
weigh the risks. The third was whether a publicly funded 
randomized trial of endovascular therapy for MS should 
be initiated now. 
The first two questions are largely ones of science, and 
are best addressed by highly qualified experts who rep-
resent the diversity of views in the scientific community. 
However, we believe that although the third question 
must  be  informed  by  science,  it  should  be  addressed 
using  a  broader  perspective.  A  clinical  trial  of  endo-
vascular treatment funded by the CIHR or provincial 
governments  would  consume  public  resources,  which 
are  clearly  limited.  Given  the  controversy,  and  given 
the way this issue has galvanized the public, the deci-
sion about whether to conduct a clinical trial should be 
informed by the public. We believe that members of the 
public, beyond 3 employees of the MS Society and one 
anonymous person with MS, should have been included 
on the Joint Invitational Meeting panel.  By “members of 
the public,” we do not mean only patients with multiple 
sclerosis or advocates for MS patients, but also thought-
ful citizens without MS who can consider all points of Open Medicine 2010;4(4):e199
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We agree with this statement and suggest that, in the 
future, members of the public should be more actively 
involved in scientifically based, but patient-relevant and 
emotionally charged, issues considered by the CIHR, by 
other Canadian research organizations and by the prov-
incial, territorial and federal governments.
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